Verastem, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Verastem, Inc. (VSTM) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 20.94 million shares for the 3-month period ending 2018-12-31, per its 10-K filed 2020-03-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2021-03-18
- Verastem, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2018-12-31 was 20.94M shares.
- Verastem, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2018 was 20.94M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|
| 2018-12-31 | 20.94M shares 10-K · filed 2020-03-11 | 20.94M shares 10-K · filed 2020-03-11 | 20.94M shares 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |